| Followers | 0 |
| Posts | 2177 |
| Boards Moderated | 0 |
| Alias Born | 04/13/2018 |
Wednesday, July 01, 2020 8:49:29 PM
None of that is actionable.
1. Uplist
Nader has stated they are applying to the NYSE under exception 4a. They have to meet with the exchange and discuss why that applies to them. Getting on an exchange takes months.
Nothing actionable in saying the company has decided to try and uplist.
2. 50 million in financing.
Nader has stated they are seeking financing and shopping lenders. They have a few discussions on the table. If not there is the 100 million shares to ready to fund the company.
Nothing actionable about stating the company is seeking financing, that it is involved in discussions and it's intentions moving foward.
3. 2 billion in revenue in 2020.
During Nader's conference call he stated based on the number of vials they believe can be produced, the need of the market, that they projected 2 billion in potential revenue.
Nothing actionable in a CEO making statements that upon approval the company projects a potential revenue from it's new drug and the demand from the market. Otherwise the NYSE, NASDAQ and other exchanges would grind to a complete halt as projecting earnings suddenly becomes a crime.
4. Looks kind of haggard.
Fresh pressed suit, well tied Windsor knot, brilliant white shirt. Appears well groomed. No bags under the eyes, no discoloration from lack of sleep, no ruddy complexion from alcohol abuse. Shoulders are squared and good posture.
I would say using the word haggard is inappropriate and an incorrect analysis of his appearance.
MYTHS BUSTED
1. Uplist
Nader has stated they are applying to the NYSE under exception 4a. They have to meet with the exchange and discuss why that applies to them. Getting on an exchange takes months.
Nothing actionable in saying the company has decided to try and uplist.
2. 50 million in financing.
Nader has stated they are seeking financing and shopping lenders. They have a few discussions on the table. If not there is the 100 million shares to ready to fund the company.
Nothing actionable about stating the company is seeking financing, that it is involved in discussions and it's intentions moving foward.
3. 2 billion in revenue in 2020.
During Nader's conference call he stated based on the number of vials they believe can be produced, the need of the market, that they projected 2 billion in potential revenue.
Nothing actionable in a CEO making statements that upon approval the company projects a potential revenue from it's new drug and the demand from the market. Otherwise the NYSE, NASDAQ and other exchanges would grind to a complete halt as projecting earnings suddenly becomes a crime.
4. Looks kind of haggard.
Fresh pressed suit, well tied Windsor knot, brilliant white shirt. Appears well groomed. No bags under the eyes, no discoloration from lack of sleep, no ruddy complexion from alcohol abuse. Shoulders are squared and good posture.
I would say using the word haggard is inappropriate and an incorrect analysis of his appearance.
MYTHS BUSTED
Recent CYDY News
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/08/2026 09:15:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/08/2026 12:30:28 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/25/2026 09:16:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:24:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:23:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:22:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:21:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 09:15:24 PM
- CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer • GlobeNewswire Inc. • 03/24/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/09/2026 09:15:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2026 01:35:02 PM
- CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab • GlobeNewswire Inc. • 03/05/2026 01:30:00 PM
- CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference • GlobeNewswire Inc. • 02/20/2026 01:30:00 PM
- CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer • GlobeNewswire Inc. • 01/27/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/09/2026 10:15:22 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 01/09/2026 01:30:45 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/22/2025 10:15:23 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 12/17/2025 05:15:14 AM
- December 2025 Letter to Shareholders • GlobeNewswire Inc. • 12/16/2025 01:30:00 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 12/10/2025 10:16:32 PM
- CytoDyn to Showcase PD-L1 Upregulation and Improved Survival in Metastatic Triple Negative Breast Cancer at the San Antonio Breast Cancer Symposium • GlobeNewswire Inc. • 12/08/2025 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/02/2025 10:15:21 PM
